BAX 555

Drug Profile

BAX 555

Alternative Names: 5-HMF - AesRx; 5-hydroxymethyl furfural; Aes-103

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Virginia Commonwealth University
  • Developer AesRx; National Institutes of Health (USA)
  • Class Antianaemics; Small molecules
  • Mechanism of Action Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 17 Sep 2015 No recent reports on development identified - Phase-I/II for Sickle cell anaemia in USA (PO)
  • 09 Jul 2014 AesRx has been acquired by Baxter International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top